BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34288191)

  • 1. Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Grimson F; Hermans R; Chaib C; Lacoin L; Juarez-Garcia A; Daumont MJ; Penrod JR; Bento MJ; Gonçalves FR
    Eur J Cancer Care (Engl); 2021 Nov; 30(6):e13496. PubMed ID: 34288191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.
    Blackhall F; Girard N; Livartowski A; McDonald L; Roset M; Lara N; Juarez García A
    BMJ Open; 2023 Feb; 13(2):e052556. PubMed ID: 36746549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.
    Tendler S; Zhan Y; Pettersson A; Lewensohn R; Viktorsson K; Fang F; De Petris L
    Acta Oncol; 2020 Apr; 59(4):388-394. PubMed ID: 31910696
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting.
    Kassik MT; Vordermark D; Kornhuber C; Medenwald D
    Radiat Oncol; 2023 Apr; 18(1):70. PubMed ID: 37072833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy.
    Coutinho AD; Shah M; Lunacsek OE; Eaddy M; Willey JP
    Lung Cancer; 2019 Jan; 127():53-58. PubMed ID: 30642551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
    Cramer-van der Welle CM; Schramel FMNH; van Leeuwen AS; Groen HJM; van de Garde EMW;
    Eur J Cancer Care (Engl); 2020 Sep; 29(5):e13250. PubMed ID: 32406593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
    Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of survival following anti-cancer treatment for small cell lung cancer.
    Jones GS; Elimian K; Baldwin DR; Hubbard RB; McKeever TM
    Lung Cancer; 2020 Mar; 141():44-55. PubMed ID: 31955000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
    Wang C; Jin S; Xu S; Cao S
    Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
    He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
    Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
    Kim H; Choi E; Heo MH; Kim JY; Park KU
    Oncology; 2022; 100(6):313-319. PubMed ID: 35390786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
    Shirasawa M; Fukui T; Kusuhara S; Hiyoshi Y; Nakahara Y; Nishinarita N; Igawa S; Naoki K
    BMC Cancer; 2019 Feb; 19(1):163. PubMed ID: 30808322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
    Su Y
    Ai Zheng; 2006 Dec; 25(12):1569-72. PubMed ID: 17166389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of integrated 18F-FDG PET-CT as a staging tool for limited-stage small cell lung cancer: a retrospective study.
    Sohn BS; Lee DH; Kim EK; Yoon DH; Kim HO; Ryu JS; Kim SW; Suh C
    Onkologie; 2012; 35(7-8):432-8. PubMed ID: 22846975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy.
    Stanic K; Vrankar M; But-Hadzic J
    Radiol Oncol; 2020 Jul; 54(3):353-363. PubMed ID: 32726294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
    Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
    J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.